Physician profile
Sara E Dube
NPI 1962434803
$2,972.17
in general payments reported to CMS, 2019-2025
14 companies · $661 in 2025
The $661 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $237 · 2023: $836 · 2024: $1,041 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,538.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $1,057.61 | 2023-2025 | Assure Wcd |
| Heartflow, INC. | $648.38 | 2024-2025 | |
| Pfizer INC. | $192.01 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $183.04 | 2021-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $175.09 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $135.78 | 2021-2023 | Camzyos |
| Amgen INC. | $134.36 | 2022-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.97 | 2025 | Jardiance |
| Philips North America LLC | $98.26 | 2023-2024 | (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und |
| Boston Scientific Corporation | $96.23 | 2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $53.74 | 2021-2024 | |
| Cvrx, INC. | $33.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.68 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $17.33 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Dube listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.